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Abstract
This article describes methods and issues that are specific to the assessment of change in tumor characteristics as
measured using quantitative magnetic resonance (MR) techniques and how this relates to the establishment of quan-
titative MR imaging (MRI) biomarkers of patient response to therapy. The initial focus is on the various sources of bias
and variance in themeasurement ofmicrovascular parameters and diffusion parameters as such parameters are being
used relatively commonly as secondary or exploratory end points in current phase 1/2 clinical trails of conventional
and targeted therapies. Several ongoing initiatives that seek to identify the magnitude of some of the sources of mea-
surement variations are then discussed. Finally, resources being made available through the National Cancer Institute
Reference Image Database to Evaluate Response (RIDER) project that might be of use in investigations of quantitative
MRI biomarker change analysis are described. These resources include 1) data from phantom-based assessment of
system response, including short-term (1 hour) and moderate-term (1 week) contrast response and relaxation time
measurement, 2) data obtained from repeated dynamic contrast agent–enhanced MRI studies in intracranial tumors,
and 3) data obtained from repeated diffusion MRI studies in both breast and brain. A concluding section briefly dis-
cusses issues that must be addressed to allow the transition of MR-based imaging biomarker measures from their
current role as secondary/exploratory end points in clinical trials to primary/surrogate markers of response and, ulti-
mately, in clinical application.
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Introduction
The wide range of image contrast mechanisms provided by magnetic
resonance imaging (MRI) techniques and the continuous improve-
ments in imaging acquisition rates have led to substantial interest
in the application of ever-expanding quantitative MRI biomarkers’
applications, particularly in phase 1/2 clinical trials of novel therapeu-
tics and combination therapies. Whereas MR-based measures of le-
sion size, for example, Response Evaluation Criteria in Solid Tumors
(RECIST)measures (http://imaging.cancer.gov/clinicaltrials/imaging/),
are perhaps not as commonly used compared with computed tomog-
raphy (CT), MR techniques that assess functional characteristics of le-
sions and normal tissue are available. Such functional MR techniques
include, but are not limited to, those that provide an assessment of
microvascular parameters, such as volume, flow, and permeability, and
those that provide an assessment of cellular volume/density parameters
as reflected in changes in water diffusion rates. Whereas such measures
are currently being used in phase 1/2 clinical trials, very few investiga-
tions into the sources of measurement variance and bias, and the miti-
gation of such effects, have been reported. Such investigations, however,
are critical to the transition from successful applications of such tech-
niques in a limited number of isolated facilities to the routine use of such
applications in multicenter clinical trials and, ultimately, to the routine
use of such techniques in patient care.
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It should not be surprising that the wide range of image contrast
mechanisms and functional imaging applications available using MR
techniques gives rise to an equally wide range of sources of variance
and bias, with several such sources discussed by Tofts [1]. Accordingly,
both the assessment of such sources and the means for mitigating their
effects must be matched to the specific application. In this report, the
main sources of variance and bias have been broken into three major
groups, with the understanding that there may be significant inter-
actions between sources of variance (e.g., covariances) between effects.
These include 1) patient-related factors, 2) acquisition-dependent fac-
tors, and 3) image analysis factors.
Primary Sources of Bias and Variance in MR Imaging
Biomarker Applications
Patient-related factors. These factors are addressed primarily in the
companion manuscript focused on non–modality-dependent factors,
so only those issues specific to MR studies are discussed. The primary
MR application factor, of course, relates to voluntary and involuntary
patient motion and/or lesion motion. In MR, such motions can lead to
a variety of artifacts and will often strongly affect measurement variance.
The untoward effects of motion can, in many cases, be minimized by
appropriate choice of the frequency- and phase-encoding directions, by
using respiratory compensation and/or respiratory gating techniques
(and/or cardiac gating techniques), or by using navigator echo tech-
niques. Lesion location can strongly affect measurement variance due
to lesion motion and/or motion of nearby normal tissues, for example,
dynamic contrast agent-enhanced (DCE) studies of lesions near the
heart and/or great vessels. In addition, effects due to therapies other
than the target therapy in a given clinical trial may affect measurement
variance, for example, steroids, particularly if the dose is varied during
treatment. Finally, some MRI biomarkers of interest, including blood
flow and blood volume, are affected by injection technique (site and rate
of injection, use of saline flush), prandial status, caffeine consump-
tion, and so on. Minimization of such patient-related factor variance
is a very important, albeit often underappreciated, component of good
study design.
Scanner hardware and acquisition-dependent factors. Fundamen-
tally, the lower limits on measurement variance and bias are established
by MR scanner calibration and stability and other hardware-related fac-
tors. Important factors in this regard include the magnetic field homo-
geneity, the radiofrequency subsystem calibration and stability, the
gradient subsystem calibration and stability, gradient nonlinearity correc-
tions (in-plane and, for some scanners and pulse sequences, through-
plane), and radiofrequency (B1) homogeneity and receiver coil sensitivity
characteristics. Variance in imaging biomarker measures due to imaging
hardware design and performance characteristics can be particularly
problematic in MR applications where there are substantial differences
in, for example, gradient subsystem performance and associated image
acquisition rates. Equally important, if not more so, are numerous
sources of variance across systems due to specific imaging protocol im-
plementations. The contrast response for a particular pulse sequence
class, for example, fast spoiled gradient echo, varies across vendors and
field strengths and can also vary across software releases for a given
vendor’s platform. It is widely recognized that for studies for which re-
peat measurements will be obtained, for example, measurement of MRI
biomarkers before and during or after therapy, requiring that the imag-
ing be performed on the same MR system can be useful for decreasing
measurement variance. This requirement, however, canmake scheduling
the studies more challenging and can also be subverted in practice by
software and/or hardware upgrades, which can have a substantial effect
on the measured parameter(s). This “upgrade dilemma” is a significant
challenge in MR studies because software upgrades are frequent and
are desirable to maintain “state-of-the-art” imaging capabilities. More
advanced acquisition strategies, such as parallel imaging options, and
image intensity correction techniques can have a substantial impact on
MRI biomarker measurement variance, particularly in a multicenter
study. Undoubtedly, a rigorous quality assurance program is critical to
the minimization of measurement variance and bias. Unfortunately,
such programs are relatively uncommon in MR facilities. With some
notable exceptions, MR quality assurance programs are either non-
existent (beyondwhat is required by the vendor’s preventivemaintenance
procedures) or are based on quality assurance programs, such as the
American College of Radiology MR Accreditation Program, which were
established to achieve goals that are not specifically related to quantitative
imaging biomarker studies.
Image analysis factors. Most of the general image analysis sources
of bias and variance are addressed in the companion manuscript on
non–modality-dependent factors. However, there are some analysis
factors that are unique to MR applications, including image inten-
sity corrections to account for variations in B1 radiofrequency coil sen-
sitivity characteristics.More advancedMRI biomarker applications, such
as DCE-MRI, are particularly dependent on image analysis fac-
tors, including vascular input function characterization, native tissue
T1 relaxation time measurements, imaging biomarker parameter nor-
malization factors, and pharmacokinetic modeling assumptions, and
algorithm implementations.
Interactions between sources of variance. As also noted in the
companion articles [2–5], there are known and, undoubtedly, as yet
unknown interactions between some of the aforementioned sources of
variance, and these must be addressed in an application specific manner.
Methods
RIDER Investigations into Sources of Bias and Variance for
MR Measures
In preliminary investigations performed by the authors under the
auspices of the RIDER initiative, the techniques investigated were those
most commonly used currently in phase 1/2 clinical trials. Compa-
nion articles discuss generic challenges related to quantitative imaging
[2] and the importance of addressing these challenges [3]. Additional
companion articles discuss modality-specific quantitative imaging issues
as related to volume computed tomography and positron emission
tomography/computed tomographymeasures [4,5]. This report discusses
issues related to quantitative imaging applications using DCE-MRI and
diffusion-weighted (DW) and diffusion tensor imaging (DTI)MRI tech-
niques. Deidentified source image data and data analyses from each of the
three projects were uploaded to the National Cancer Institute’s National
Biomedical Imaging Archive (NBIA, http://ncia.nci.nih.gov/collections).
Three specific subprojects were developed:
Project 1: Phantom data obtained on four scanners from two
vendors and at two field strengths to address 1) repeatability
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(short-term and long-term) of T1 measurements, 2) contrast-to-
noise ratio and signal intensity stability, 3) limits of agreement of
T1 measurements using two acquisition techniques, and 4) be-
tween-vendor contrast differences and effect on computed contrast
agent concentration results. (Institution A)
Project 2: Repeat, that is, assumed zero pathologic change, DCE-
MRI and DT-MRI of brain tumors in patients with recurrent
glioblastoma multiforme. The data obtained using DCE-MRI
techniques, when appropriately analyzed using pharmacokinetic
models, provide a means of assessing the endothelial transfer con-
stant (K trans), which describes the rate of contrast agent transfer
from the vascular space to the extravascular, extracellular space
(EES) and, particularly with currently approved low–molecular
weight contrast agents, represents the extraction-flow product,
kep, the reflux rate of the contrast agent from the EES back to
the vascular space, vp, the vascular volume fraction, and ve, the
EES volume fraction. The data obtained using DT-MRI tech-
niques can be used to assess the apparent diffusion coefficient
(ADC) and fractional anisotropy (FA) within enhancing lesions
in these patients. (Institution B)
Project 3: Repeat, that is, assumed zero pathologic change, DW
and ADC MRI of breast lesions. Changes in ADC have been
previously demonstrated to compare favorably with changes in
cellular volume fraction or density. (Institution C)
The three projects were chosen to satisfy the general goals of the
RIDER group at large and were designed to address the following
specific issues:
Accuracy, bias, and reproducibility using a test object:
Accuracy: If the same phantom is rescanned on the same
device, how much variance is observed?
Reproducibility: If the phantom is scanned on a different
device (same vendor as well as different vendor), how
much variance is observed?
Bias: How closely, on average, can acquisitions on one ven-
dor’s scanner be matched on a scanner, at the same field
strength, from a different vendor?
Patient accuracy:
If repeated scans are obtained on a given patient under a
zero pathologic change assumption, how much variation is
observed when the same acquisition, image analysis, and
image-derived measurement calculation are used?
A third primary goal, focused on outcome measures, could not be ad-
dressed in the short period during which these studies were completed.
This third important question addresses the critically important question
of MRI biomarker change in patients, that is, when a patient is imaged
over time, how much change can reliably be observed, and how well
does such a change predict subsequent clinical outcome?
Each project provided to RIDER deidentified source data as well as
results of test-retest reproducibility. All data and analyses have been
made available through the NBIA so that they might be used by other
researchers interested in change analysis in DCE-MRI, DW/ADC-
MRI, or DT-MRI.
MR Data Made Publicly Available through RIDER on the
NCI NBIA
Project 1: Phantom data to assess system bias and variance (Insti-
tution A). Data were obtained using an 18-compartment EuroSpin
TO5 contrast response phantom (Diagnostic SONAR, Ltd, Livingston,
West Lothian, Scotland). Data were obtained in “coffee break” fashion
on the same day as well as 1 week later. In the coffee break measure-
ment setting, the radiofrequency coil and phantom were positioned
and data obtained and the phantom was then removed and positioned
and scanned on a second nearby scanner. The phantomwas subsequently
returned to the first scanner, the radiofrequency coil and phantom were
repositioned, and the data were obtained using a new examination
ID but using the same stored data acquisition protocol. Data were ob-
tained at all three time points from three 1.5-T scanners (two with
differing gradient subsystems from a single vendor and one from a sec-
ond vendor) and from one 3.0-T scanner. Data acquired included T1
measurements using a two-dimensional inversion recovery (IR) se-
quence (once at 1.5 T and twice at 3.0 T) and a three-dimensional
multiple flip angle fast-spoiled gradient-recalled echo (MF-FSPGR) se-
quence (each time on each scanner). A DCE-MRI data set was also
acquired each time on each scanner using a three-dimensional FSPGR
sequences with sections matching those acquired for the MF-FSPGR
T1 measurements.
For the fast spin-echo IR T1 measurements, 10 inversion times
were used (50, 100, 250, 500, 750, 1000, 1500, 2000, 2500, and
3000 milliseconds). For the MF-FSPGR T1 measurements, seven flip
angles were used (2°, 5°, 10°, 15°, 20°, 25°, and 30°). For the DCE-
MRI acquisitions, the total scan time was approximately 7 minutes with
a temporal resolution of approximately 9 seconds (dependent on spe-
cific scanner). Echo (TE) and repetition times (TR) were matched
as closely as possible across scanners, with TE ranging from 0.90 to
1.35 milliseconds and TR ranging from 4.09 to 5.10 milliseconds.
The flip angle was 30° for all DCE-MRI scans. For all acquisitions,
the field of view was 24 × 19 cm, the acquisition matrix was 256 ×
192, and the acquisition bandwidth was ±31.25 kHz.
Project 2: Repeated DCE-MRI and diffusion tensor imaging data
in brain tumor patients (Institution B). In this study, repeat
DCE-MRI data sets in 19 patients with recurrent glioblastoma multi-
forme and repeat diffusion tensor imaging (DTI) data sets in 17 of the
19 patients were performed. The interval between scans was 2 days
or less. All images were obtained on the same 1.5 T scanner (Siemens
Avanto, SiemensMedical Solutions,USA, Inc,Malvern, PA). In brief, for
DCE-MRI, T1 mapping using a multiflip angle approach with six flip
angles was performed. Dynamic imaging was performed every 4.8 sec-
onds during the intravenous infusion of 0.1 mmol/kg of gadolinium–
diethylenetriamine penta-acetic acid at 3 ml/sec. DTI was performed
using a 12 diffusion-sensitizing gradient direction sequence, TR of
6000 milliseconds, TE of 100 milliseconds, flip angle of 90°, signal
averages of four, acquisition matrix of 128 × 128, voxel size of 1.7 ×
1.7 × 5.0 mm, and a b value of 1000 sec/mm2.
In addition to the source data, parameter maps for fractional plasma
volume, volume of the extracellular extravascular space, and K trans
(from theDCE-MRI data), and ADC and FA (from theDTI data) were
transferred to the NBIA. Segmentations of tumor-related enhancement
and fluid-attenuated IR (FLAIR) signal abnormality volumes were
also transferred.
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Project 3: Repeated ADC diffusion of breast cancer (Institution C).
In this study, during the first cycle of neoadjuvant chemotherapy, the
following imaging protocol was implemented:
1. Two preinitiation (pretherapy) baseline MRI scans were typically
obtained within 15 minutes, where initiation of neoadjuvant
chemotherapy was no later than 1 week from the last baseline
MRI; and
2. One postinitiation MRI was obtained within 8 to 11 days after
initiation of neoadjuvant chemotherapy
The second cycle of neoadjuvant chemotherapy was implemented
with no further imaging studies. In brief, the data were acquired in
the axial plane using a Philips 3 T scanner (Philips Medical System,
Eindhoven, the Netherlands) and the following acquisition parameters:
field of view = 350 mm; acquisition matrix = 196 × 86; sensitivity en-
coding factor 2; 30 4-mm-thick sections; two-dimensional spin-echo–
echo-planar imaging three-axis DWI at b = 0 and 800 sec/mm2; short
tau IR (fat suppression), TR/TE/TI = 12,000/62/150 milliseconds; sig-
nal average = 2; acquisition time = 4 hours 41 minutes.
Analyses of Bias and Variance
For each project, analyses of bias and variance were performed
as follows:
Project 1. Limits of agreement and coefficients of repeatability, as
proposed by Bland and Altman [6], were computed for the T1 measure-
ments obtained from each scanner using the IR-based and multiple flip
angle–based data (limits of agreement) or multiple flip angle measure-
ments at each time point (coefficients of repeatability) [7]. T1 measure-
ment correlation analysis was also performed using the data obtained at
each time point on each scanner. Contrast response was assessed at each
time point on each scanner using the multiple compartment phantom
data, and stability of the CNR and signal intensity was assessed from
each of the DCE scans obtained at each time point on each scanner.
Simulated DCE uptake curves were also generated for each scanner
using measured data from the multiple compartment phantom and
commonly assumed signal intensity response for an ideal fast spoiled
gradient echo sequence.
Project 2. A similar analysis of repeatability was performed on both
the DCE-MRI and DTI data sets from brain tumor patients. For
DCE-MRI parameters, mean values were obtained at both time points
in areas of tumor-related enhanced segmented from three-dimensional
isotropic T1-weighted contrast-enhanced FLASH images. The coeffi-
cient of repeatability (Bland and Altman [6]) and the 95% confidence
interval for percent change in parameter were computed [8,9]. For DTI
parameters, mean values were obtained at both time points in both the
areas of tumor-related enhancement and the areas of FLAIR signal ab-
normality segmented from the three-dimensional isotropic contrast-
enhanced FLAIR images [10].
Project 3. Registration of the tumor in the interval examinations
was implemented using MIAMI Fuse. Tumor volumes of interest were
drawn on the anatomic image volume and were warped from the ana-
tomic volume onto one of the pretherapy diffusion volumes denoted as
the reference; warping is necessary owing to the susceptibility artifacts
in the diffusion acquisitions that are not present in the anatomic vol-
umes. Subsequent registrations, either between the two pretherapy ex-
aminations or the two pretherapy and posttherapy scans, were also
warped to account for repositioning deformations to the breast as well
as any small compartmental changes to the tumor. Warping was accom-
plished using thin-plate splines where the degrees of freedom (DOF) of
the warp are related to the volume of the tumor. The user only needed to
pick the location of three control points in the homologous tumor vol-
ume that approximate their loci in the reference tumor volume. The
multiscale registration first implemented rigid-body registration, then
low DOF warping, and finally full DOF warping.
ADC volumes were computed from the interleaved b = 0 sec/mm2
and b = 800 sec/mm2 acquisitions. For each pair of registered ADC
images, a 128 × 128 joint density histogram ( JDH) was constructed by
incrementing the count of the two-dimensional histogram defined by
the two ADC values of the registered tumors. For the JDH of the two
pretherapy examinations, bias was removed from this realization and
variance was generalized, that is, increased, by adding the transpose
of its JDH to itself. Linear regression was then performed after rotating
the JDH onto its principal component axes. The resulting linear esti-
mate, the estimates of its 95% confidence limits, and the 95% confi-
dence limits of the JDH were computed and plotted on the modified
JDH. The means of both JDHs were computed and plotted. Note that
the pretherapy/pretherapy JDH represents estimates of sources of noise
associated with the null hypothesis, that is, the presence of all sources
of noise encountered in estimating change between short-interval ex-
aminations, but no change in the tumor [11,12].
The detailed results from the analyses of bias and variance for each of
the three projects will be provided on the NBIAWeb site (http://ncia.
nci.nih.gov/collections), along with all source data, and are not repli-
cated in this article in the interest of brevity.
All human subject studies were approved by the respective institu-
tional review board and written informed consent was provided by
each subject.
Discussion and Conclusions
The focus of this article, like its companion articles addressing other
modalities [4,5], has been the identification of sources of bias and
variance and the measurement of bias and variance at the system level
(phantommeasures) and patient level (“coffee break” studies) in studies
focused on applications of DCE-MRI, DW-MRI, and DT-MRI. The
data obtained and analyzed by the authors, and made available through
RIDER on the NCI NBIA, were described along with the rationale
for the selection of these particular projects.
The characterization and investigations of the sources of bias and
variance introduced in this article are essential, but are clearly not suf-
ficient, for the establishment of theMRI biomarkers investigated in this
study as surrogate markers of response. This essential remaining step
requires carefully designed, multicenter trials with standardized acqui-
sition protocols, quality assurance programs, and outcome measures
highly correlated with disease status.
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